Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer. - Wikidata - awgldk - TriplyDB

Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.

Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.

http://www.wikidata.org/entity/Q37360194

about

Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells.The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients.The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma.Herceptin resistance database for understanding mechanism of resistance in breast cancer patients.Identifying responders to trastuzumab therapy in breast cancer.De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer.Assessment of Specificity of an Adenovirus Targeted to HER3/4.HER2 FISH results in breast cancers with increased CEN17 signals using alternative chromosome 17 probes - reclassifying cases in the equivocal category.The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition.Immunohistochemical analysis of the monoclonal antibody 4B5 in breast tissue expressing human epidermal growth factor receptor 4 (HER4).The FlexISH assay brings flexibility to cytogenetic HER2 testing.

P2860

Q27303674-F1F7B138-2366-44D8-BD2D-C007A4AB5FB8 Q27853060-EDE94832-F372-4296-9E99-901520D7BC19 Q34428718-AC67431A-95AF-4E6F-AF4A-D193084C171B Q34996222-D5AF4C25-43E5-4098-A8FE-290CD4CEEC9C Q36064912-6804BF7A-9C5E-4E57-A918-B6D9A04AC05A Q37381593-5268C926-44C6-4883-B106-FB0B22E4C60F Q37666730-61A49D8E-5965-49F2-9313-E4B57F5E28E1 Q37889967-5F8D2982-0400-4BD3-B7F3-4BCCC8EBAB78 Q38563592-1EAAF557-026E-402B-8A7E-0821AA5D24DF Q38591976-948D6F13-AA48-47BB-9387-F121D69C9443 Q38645041-B0565652-967D-40CD-B907-7072D1A7DEC5 Q48147789-3EB86697-EBBE-4F2E-9FFC-015D17FFBA77 Q52657273-DDC04836-837C-470F-9C57-035916862806 Q54448091-65836825-88F5-49B4-956D-5A01D088AB16 Q55026325-0609AF1F-8285-4A86-99A4-2A888C79B74F

P2860

Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.

http://www.wikidata.org/entity/Q37360194

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Presence of HER4 associates wi ...... with metastatic breast cancer.

@en

Presence of HER4 associates wi ...... with metastatic breast cancer.

@nl

type

label

Presence of HER4 associates wi ...... with metastatic breast cancer.

@en

Presence of HER4 associates wi ...... with metastatic breast cancer.

@nl

prefLabel

Presence of HER4 associates wi ...... with metastatic breast cancer.

@en

Presence of HER4 associates wi ...... with metastatic breast cancer.

@nl

P1433

Q37360194-48F732F6-CE14-434C-9E06-55661739E334

P1476

Q37360194-F846093B-90AD-47D5-8F55-2BFA2AF6A57A

P2093

Q37360194-181B6E61-3110-4A04-8B53-578D77FAE0A6

Q37360194-241F8708-1D79-4B6A-96F3-4E9F030391B9

Q37360194-421BE5C1-0DFA-4A18-BCE1-7309EA59AA35

Q37360194-A1A5CD4B-CDFA-4ED3-8563-9690B3A9455C

Q37360194-C46725BB-B7D6-44B9-9A80-83AE57193463

Q37360194-CF55E264-673A-49E8-9B8C-A53597C7CE3C

Q37360194-DFF40BC2-8FCB-4125-BD14-E7D813414B35

P2860

Q37360194-01745A7B-B84A-4A2C-B1CE-CA9FE9306F69

Q37360194-0A4C4AB5-1A63-40C5-908A-ED147B7EA9F3

Q37360194-0CD02B7D-8426-4788-9286-6876137E1713

Q37360194-10A60ACB-A6FF-4971-B1A2-CF5A14696729

Q37360194-10C30F1F-D60D-496D-AD73-9F73D75D9C9D

Q37360194-1410CBD1-962B-451B-8EB6-6E111087872F

Q37360194-1540BE12-AFCE-4457-A73D-4E369770AC39

Q37360194-1DBDA22D-C74E-4F4F-9764-C41FC10B51C1

Q37360194-21DB6F7E-1C61-4179-8F0A-3FD52ABBF817

Q37360194-24D5E878-9F93-44A5-8C21-3496B4B9B673

P2888

Q37360194-7B1CCF63-9A18-4D52-8665-1E5B1F4B4F06

P304

Q37360194-928A35D9-EAD4-4EDF-B0E6-7D57E15B12FC

P31

Q37360194-D9724233-2678-47C2-AA7B-C9D917CEC38F

P356

Q37360194-98A67C75-5DF4-48C6-89DD-D2032B0CCD66

P433

Q37360194-6FE69145-93CF-45BF-B1E8-EA8A0594E55B

P478

Q37360194-86FD2D82-18C1-42E8-B049-2A1A8C0024BE

P50

Q37360194-5ED8551D-4352-4840-BEB2-079500FE4913

Q37360194-FDADCBEC-7528-4801-AC01-73081D021C8F

P577

Q37360194-6994D6A7-6134-4790-99A8-1152A6579929

P5875

Q37360194-87B4B9D0-E83F-4746-BFDC-B566BAC06B97

P6179

Q37360194-DED51F9F-9ECD-435E-A8FE-E308B208AB9B

P698

Q37360194-9CE4510E-6953-4218-AC6E-5C003C44C110

P932

Q37360194-AF40E4B6-E7E2-4ED6-8E2C-FE6D2CC07A78

P356

P1433

Breast Cancer Research

P1476

Presence of HER4 associates wi ...... with metastatic breast cancer.

@en

P2093

Andrea Sassen

http://www.w3.org/2001/XMLSchema#string

Ferdinand Hofstaedter

http://www.w3.org/2001/XMLSchema#string

Gero Brockhoff

http://www.w3.org/2001/XMLSchema#string

Manuela Sieben

http://www.w3.org/2001/XMLSchema#string

Olaf Ortmann

http://www.w3.org/2001/XMLSchema#string

Simone Diermeier-Daucher

http://www.w3.org/2001/XMLSchema#string

Stephan Schwarz

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase

The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells

The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone

Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

The cyclin dependent kinase inhibitor p27 and its prognostic role in breast cancer.

Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling

Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases

Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

P2888

P304

R50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR2339

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Simone Diermeier-Daucher

P577

2009-07-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26688268

http://www.w3.org/2001/XMLSchema#string

P6179

1012977254

http://www.w3.org/2001/XMLSchema#string

P698

19624808

http://www.w3.org/2001/XMLSchema#string

P932

2750111

http://www.w3.org/2001/XMLSchema#string